Reduced variability of neoral pharmacokinetic studies in pediatric renal transplantation

Pediatric Nephrology

Volumn 15, Issue 1-2, 2000, Pages 2-6

  Portman, R J ^a   Meier Kriesche, H U ^a   Swinford, R ^a   Brannan, P ^b   Kahan, B D ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Memorial Hermann Children's Hospital   (United States)

Author keywords

AUC; Neoral; Pediatrics; Pharmacokinetics; Renal transplantation

Indexed keywords

CYCLOSPORIN A;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 0033671604     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004670000435     Document Type: Article

References (26)

1. Effect of cyclosporine A on long-term allograft function in pediatric renal transplant recipients
2. Pediatric renal transplantation at the University of Minnesota: The cyclosporine years
3. Progress in renal transplantation for children
4. Higher maintenance cyclosporine dose decreases the risk of graft failure in North American children: A report of the North American Pediatric Renal Transplant Cooperative Study
5. Improved absorption of cyclosporin A from a new microemulsion formulation: Implications for dosage and monitoring
6. Clinical pharmacokinetics of Neoral in pediatric recipients of primary liver transplants
7. Pharmacokinetics of cyclosporine in pediatric long-term liver transplant recipients converted from Sandimmune to Neoral
8. The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients
9. Cyclosporin pharmacokinetics following administration of capsules and Neoral in paediatric patients with lupus nephritis
10. Comparison of Neoral and Sandimmune cyclosporin A pharmacokinetic profiles in young renal transplant recipients
11. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals
12. Improved cyclosporine pharmacokinetics in maintenance renal transplant recipients converted to cyclosporine for microemulsion
13. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation
14. Within-day consistency in cyclosporine pharmacokinetics from a microemulsion formulation in renal transplant patients
15. Neoral induction in pediatric renal transplantation
16. Renal function following conversion from Sandimmune to Neoral in stable renal transplant recipients
17. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation
18. Switching between cyclosporin formulations. What are the risks?
19. A limited sampling strategy to predict the Sang-35 area under the curve (AUC) in adult renal transplant recipients
20. Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy. Technical note
21. Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate posttransplant period
22. Abbreviated area-under-the-curve strategy for monitoring cyclosporine microemulsion therapy in immediate posttransplant period
23. A pharmacokinetic comparison of the corn oil versus microemulsion gelcap formulation of cyclosporin used de novo after renal transplantation
24. A limited sampling strategy for the estimation of eight-hour neoral areas under the curve in renal transplantation
25. A limited sampling strategy for the estimation of Neoral AUCs in pediatric patients
26. Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection